Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Mateon Therapeutics Provides Business Update and Reports 2017 Financial Results
SOUTH SAN FRANCISCO, Calif. , April 16, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, today provided a business update and announced 2017 financial results.  Business
View HTML
Toggle Summary Mateon Therapeutics Raises Net Proceeds of Approximately $2.4 Million in Financing Transaction
SOUTH SAN FRANCISCO, Calif. , April 16, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc . (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, today announced that it has completed a private placement transaction with
View HTML
Toggle Summary Mateon Announces New Preclinical Data Demonstrating Enhanced Tumor Immune Responses when CA4P is Given in Combination with Checkpoint Inhibitors
·  CA4P and checkpoint inhibitor combination nearly doubles amount of tumor necrosis SOUTH SAN FRANCISCO, Calif. , Jan. 08, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc . (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology
View HTML
Toggle Summary Mateon Therapeutics to Present at the 2018 Biotech Showcase
SOUTH SAN FRANCISCO, Calif. , Jan. 03, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, today announced that it will present a company overview at the 2018 Biotech Showcase
View HTML
Toggle Summary Mateon Announces Preclinical Data Indicating Enhanced Tumor Immune Response of CA4P with Checkpoint Inhibitor
Addition of CA4P simultaneously reduces tumor volume and increases tumor white blood cells, T Cells and cytotoxic T Cells compared to anti-CTLA-4 monotherapy Preliminary data suggest immuno-oncology applications for drug candidate   SOUTH SAN FRANCISCO, Calif. , Dec.
View HTML
Toggle Summary Mateon Provides Corporate Update and Reports Third Quarter 2017 Financial Results
SOUTH SAN FRANCISCO, Calif. , Nov. 14, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications, today provided a corporate update and reported financial results for the three
View HTML
Toggle Summary Mateon Therapeutics Announces Updated Data from Fifth Cohort of Phase 1b Study of OXi4503 in Acute Myeloid Leukemia
New Data Continue to Show OXi4503 has Significant Potential as New Treatment for AML OXi4503 Recently Prioritized as Lead Drug Development Program at Mateon SOUTH SAN FRANCISCO, Calif. , Oct. 30, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc . (OTCQX:MATN), a biopharmaceutical company
View HTML
Toggle Summary Mateon Therapeutics Announces Termination of FOCUS Study in Ovarian Cancer and Restructuring to Prioritize OXi4503 for AML
Company to terminate FOCUS study due to lack of clear efficacy signal in the third interim analysis Company to reduce headcount, concentrate on OXi4503 for acute myeloid leukemia (AML) SOUTH SAN FRANCISCO, Calif. , Sept. 26, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc.
View HTML
Toggle Summary Mateon Therapeutics to Present at the 19th Annual Rodman and Renshaw Global Investment Conference on September 12, 2017
SOUTH SAN FRANCISCO, Calif. , Sept. 06, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents for the treatment of orphan oncology indications, today announced it will be featured as a presenting company at the 19 th
View HTML
Toggle Summary Mateon Therapeutics Announces Results from Second Interim Analysis of CA4P Phase 2/3 FOCUS Study in Platinum-resistant Ovarian Cancer
Primary Endpoint - Early Progression Free Survival data favors CA4P CA4P continues to be safe and well-tolerated Next interim analysis expected in September SOUTH SAN FRANCISCO, Calif. , Aug. 16, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing
View HTML